ANDA 77800, held by Pharmobedient. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 77800 (Levalbuterol Hydrochloride), held by Pharmobedient, was first approved by FDA on Mar 15, 2013, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 15, 2013 | Original application | Approved | None posted |
| Levalbuterol HydrochlorideEQ 0.0103% BASE · solution;inhalation | Levalbuterol Hydrochloride | Discontinued |
| Levalbuterol HydrochlorideEQ 0.021% BASE · solution;inhalation | Levalbuterol Hydrochloride | Discontinued |
| Levalbuterol HydrochlorideEQ 0.042% BASE · solution;inhalation | Levalbuterol Hydrochloride | Discontinued |
| Oct 3, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 3, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 15, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters